Search the Newsreel

REGN or INCY: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Incyte (INCY). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. …

Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company …

Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as …

European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)

In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of …

Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. …

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24, and was well tolerated 1,2,3 WILMINGTON, Del., July 29, 2026--(BUSINESS WIRE)--Incyte …

Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

This article first appeared on GuruFocus. Total Revenue: $1.67 billion, up 38% year over year. Total Net Sales: $1.49 billion, representing 40% growth year over year. Jakafi Sales: $817 million, up 7% year over year. Opzelura Sales: $450 million in the second quarter, including …

Incyte forecasts $5.130B-$5.260B 2026 net sales as Opzelura guidance rises to $1.050B-$1.1B after CMS settlement

Earnings Call Insights: Incyte Corporation (INCY) Q2 2026 MANAGEMENT VIEW * "At the start of the year, we laid out a plan to move Incyte from reliance on a cornerstone product to a company with multiple growth drivers," William Meury (CEO & Director) said, …

Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio. The company also raised its full-year 2026 sales guidance. Second-quarter net income increased to $585.6 million or $2.81 per share, from …

Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Incyte (INCY) reported revenue of $1.67 billion, up 37.7% over the same period last year. EPS came in at $3.09, compared to $1.57 in the year-ago quarter. The reported revenue represents a surprise of +14.71% over the Zacks …

Incyte (INCY) Q2 Earnings and Revenues Top Estimates

Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly

Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 37.7% year on year to $1.67 billion. On the other hand, …

What to Expect From Incyte's Q2 2026 Earnings Report

What To Expect From Incyte's (INCY) Q2 Earnings Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here's what to look for. Incyte beat analysts' revenue expectations last quarter, reporting revenues of $1.27 billion, up 20.9% year on year. …

Incyte Non-GAAP EPS of $3.09 beats by $0.94, revenue of $1.67B beats by $180M

* Incyte press release [https://seekingalpha.com/pr/20596936-incyte-reports-second-quarter-2026-financial-results-and-provides-business-updates] (INCY [https://seekingalpha.com/symbol/INCY]): Q2 Non-GAAP EPS of $3.09 beats by $0.94. * Revenue of $1.67B (+36.9% Y/Y) beats by $180M. * Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an …

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an increase of 38% and 40%, respectively, compared to the second quarter of 2025 Total net sales, excluding the one-time, non-cash benefit for Opzelura® (ruxolitinib) cream …

Incyte Q2 Earnings Preview: Can Commercial Growth Sustain A Catalyst-Rich Pipeline?

(RTTNews) - Incyte (INCY), a biopharmaceutical company, is scheduled to report second-quarter financial results on July 28, 2026. Incyte's key therapeutic areas of focus include Haematology, Oncology, Inflammation, and Autoimmunity. In addition to sales trends for Polycythemia vera drug Jakafi and Atopic dermatitis drug …

Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand …

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

Incyte (INCY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to …

Stock Incyte - Stock INCY - Resultados, Dividendos, Cotação e Indicadores